Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 3/20 | 0.60 |
| ▸ | FNTB | P49356 | 3/20 | 0.60 |
| ▸ | CRYAB | P02511 | 5/20 | 0.56 |
| ▸ | CRYAA | P02489 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19198777 | 0.92 | FNTA (0.60) | FNTAFNTBCRYABCRYAAUSP2 | |
| SCHEMBL17428554 | 0.87 | MAPT (0.56) | FNTAFNTBCRYABCRYAAUSP2 | |
| SCHEMBL5664605 | 0.85 | USP2 (0.73) | FNTAFNTBCRYABCRYAAUSP2 | |
| SCHEMBL15934959 | 0.85 | MAPT (0.53) | FNTAFNTBCRYABCRYAAUSP2 | |
| SCHEMBL17431762 | 0.84 | CRYAB (0.77) | FNTAFNTBCRYABCRYAAUSP2 | |
| SCHEMBL17428538 | 0.84 | FNTA (0.67) | FNTAFNTBCRYABCRYAAUSP2 | |
| SCHEMBL29692186 | 0.84 | CRYAB (0.77) | FNTAFNTBCRYABCRYAAUSP2 | |
| SCHEMBL17428544 | 0.84 | MAPT (0.75) | FNTAFNTBCRYABCRYAAUSP2 | |
| SCHEMBL19198710 | 0.82 | CRYAB (0.55) | FNTAFNTBCRYABCRYAAUSP2 | |
| SCHEMBL15934993 | 0.79 | CRYAB (0.78) | FNTAFNTBCRYABCRYAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522935-B2 | Commands and method of treating cancer via RHO pathway | DM INTELLIGENCE MEDICINE LTD (CN) | 2016-12-20 | — | — | US | disclosed |
| US-9522935-B2 | Commands and method of treating cancer via RHO pathway | DM INTELLIGENCE MEDICINE LTD (CN) | 2016-12-20 | — | — | US | disclosed |
| US-20160009756-A1 | Commands and method of treating cancer via RHO pathway | Xie, Weidong (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20160009756-A1 | Commands and method of treating cancer via RHO pathway | Xie, Weidong (CA) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009756-A1 | Commands and method of treating cancer via RHO pathway | RHOA, RHOT2, ROCK1 | FNTA 120/4885FNTB 444/4885CRYAB 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.